Literature DB >> 26294720

The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL.

Michaela Kotrova1, Katerina Muzikova1, Ester Mejstrikova1, Michaela Novakova1, Violeta Bakardjieva-Mihaylova1, Karel Fiser1, Jan Stuchly1, Mathieu Giraud2, Mikaël Salson2, Christiane Pott3, Monika Brüggemann3, Marc Füllgrabe3, Jan Stary4, Jan Trka1, Eva Fronkova1.   

Abstract

Mesh：

Year:  2015        PMID： 26294720      PMCID： PMC4551355          DOI： 10.1182/blood-2015-07-655159

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis.

Authors:  Jana Volejnikova; Ester Mejstrikova; Tatana Valova; Leona Reznickova; Ladislava Hodonska; Vladimir Mihal; Jaroslav Sterba; Yahia Jabali; Daniela Prochazkova; Bohumir Blazek; Jiri Hak; Zdenka Cerna; Ondrej Hrusak; Jan Stary; Jan Trka; Eva Fronkova
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

Review 2.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

3.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Malek Faham; Jianbiao Zheng; Martin Moorhead; Victoria E H Carlton; Patricia Stow; Elaine Coustan-Smith; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

Review 4.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

5.  Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

Authors:  M Ladetto; M Brüggemann; L Monitillo; S Ferrero; F Pepin; D Drandi; D Barbero; A Palumbo; R Passera; M Boccadoro; M Ritgen; N Gökbuget; J Zheng; V Carlton; H Trautmann; M Faham; C Pott
Journal:  Leukemia       Date:  2013-12-17       Impact factor: 11.528

6.  Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?

Authors:  E Fronkova; E Mejstrikova; S Avigad; K W Chik; L Castillo; S Manor; L Reznickova; T Valova; K Zdrahalova; O Hrusak; Y Jabali; M Schrappe; V Conter; S Izraeli; C K Li; B Stark; J Stary; J Trka
Journal:  Leukemia       Date:  2008-02-28       Impact factor: 11.528

7.  Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.

Authors:  David Wu; Ryan O Emerson; Anna Sherwood; Mignon L Loh; Anne Angiolillo; Bryan Howie; Jennifer Vogt; Mark Rieder; Ilan Kirsch; Christopher Carlson; David Williamson; Brent L Wood; Harlan Robins
Journal:  Clin Cancer Res       Date:  2014-06-26       Impact factor: 12.531

8.  Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

Authors:  Giuseppe Basso; Marinella Veltroni; Maria Grazia Valsecchi; Michael N Dworzak; Richard Ratei; Daniela Silvestri; Alessandra Benetello; Barbara Buldini; Oscar Maglia; Giuseppe Masera; Valentino Conter; Maurizio Arico; Andrea Biondi; Giuseppe Gaipa
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

9.  Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.

Authors:  A C Logan; B Zhang; B Narasimhan; V Carlton; J Zheng; M Moorhead; M R Krampf; C D Jones; A N Waqar; M Faham; J L Zehnder; D B Miklos
Journal:  Leukemia       Date:  2013-02-19       Impact factor: 11.528

10.  Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing.

Authors:  Mathieu Giraud; Mikaël Salson; Marc Duez; Céline Villenet; Sabine Quief; Aurélie Caillault; Nathalie Grardel; Christophe Roumier; Claude Preudhomme; Martin Figeac
Journal:  BMC Genomics       Date:  2014-05-28       Impact factor: 3.969
  10 in total
  31 in total

1.  Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?

Authors:  A Balduzzi
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

2.  Reliability of immune receptor rearrangements as genetic markers for minimal residual disease monitoring.

Authors:  V I Nazarov; A A Minervina; A Y Komkov; M V Pogorelyy; M A Maschan; Y V Olshanskaya; I V Zvyagin; D M Chudakov; Y B Lebedev; I Z Mamedov
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

3.  Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Authors:  Elias Jabbour; Nicholas J Short; Jeffrey L Jorgensen; Musa Yilmaz; Farhad Ravandi; Sa A Wang; Deborah A Thomas; Joseph Khoury; Richard E Champlin; Issa Khouri; Partow Kebriaei; Susan M O'Brien; Guillermo Garcia-Manero; Jorge E Cortes; Koji Sasaki; Courtney D Dinardo; Tapan M Kadia; Nitin Jain; Marina Konopleva; Rebecca Garris; Hagop M Kantarjian
Journal:  Cancer       Date:  2016-09-07       Impact factor: 6.860

Review 4.  Precision medicine in pediatric oncology: Lessons learned and next steps.

Authors:  Rajen J Mody; John R Prensner; Jessica Everett; D Williams Parsons; Arul M Chinnaiyan
Journal:  Pediatr Blood Cancer       Date:  2016-10-17       Impact factor: 3.167

Review 5.  Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.

Authors:  Monika Brüggemann; Michaela Kotrova
Journal:  Blood Adv       Date:  2017-11-28

6.  Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.

Authors:  M Kotrova; V H J van der Velden; J J M van Dongen; R Formankova; P Sedlacek; M Brüggemann; J Zuna; J Stary; J Trka; E Fronkova
Journal:  Bone Marrow Transplant       Date:  2017-02-27       Impact factor: 5.483

Review 7.  Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.

Authors:  Monika Brüggemann; Michaela Kotrova
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Authors:  Prisca Theunissen; Ester Mejstrikova; Lukasz Sedek; Alita J van der Sluijs-Gelling; Giuseppe Gaipa; Marius Bartels; Elaine Sobral da Costa; Michaela Kotrová; Michaela Novakova; Edwin Sonneveld; Chiara Buracchi; Paola Bonaccorso; Elen Oliveira; Jeroen G Te Marvelde; Tomasz Szczepanski; Ludovic Lhermitte; Ondrej Hrusak; Quentin Lecrevisse; Georgiana Emilia Grigore; Eva Froňková; Jan Trka; Monika Brüggemann; Alberto Orfao; Jacques J M van Dongen; Vincent H J van der Velden
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

Review 9.  High-throughput sequencing for noninvasive disease detection in hematologic malignancies.

Authors:  Florian Scherer; David M Kurtz; Maximilian Diehn; Ash A Alizadeh
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

10.  Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms.

Authors:  Maria E Arcila; Wayne Yu; Mustafa Syed; Hannah Kim; Lidia Maciag; JinJuan Yao; Caleb Ho; Kseniya Petrova; Christine Moung; Paulo Salazar; Ivelise Rijo; Tessara Baldi; Ahmet Zehir; Ola Landgren; Jae Park; Mikhail Roshal; Ahmet Dogan; Khedoudja Nafa
Journal:  J Mol Diagn       Date:  2018-12-25       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.